Seth Blackley - 15 Jun 2023 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Role
Chief Executive Officer, Director
Signature
/s/ Jonathan Weinberg, Attorney-in-fact
Issuer symbol
EVH
Transactions as of
15 Jun 2023
Net transactions value
-$2,056,761
Form type
4
Filing time
20 Jun 2023, 16:36:41 UTC
Previous filing
07 Mar 2023
Next filing
30 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVH Class A Common Stock Options Exercise $291,575 +75,931 +9.7% $3.84* 858,942 15 Jun 2023 Direct F1, F2
transaction EVH Class A Common Stock Sale $2,293,116 -75,931 -8.8% $30.20 783,011 15 Jun 2023 Direct F1, F2, F3
transaction EVH Class A Common Stock Options Exercise $8,056 +2,098 +0.27% $3.84* 785,109 16 Jun 2023 Direct F1, F2
transaction EVH Class A Common Stock Sale $63,276 -2,098 -0.27% $30.16 783,011 16 Jun 2023 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVH Class A Common Option (right to buy) Options Exercise $0 -75,931 -68% $0.000000 35,109 15 Jun 2023 Class A Common Stock 75,931 $3.84 Direct F1, F5
transaction EVH Class A Common Option (right to buy) Options Exercise $0 -2,098 -6% $0.000000 33,011 16 Jun 2023 Class A Common Stock 2,098 $3.84 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.
F2 Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.52, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.09 to $30.16, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The Class A Common Stock Options exercised vested on December 1, 2017.